[*QUOTE*]
-------------------------------------------------
Radioaktive Trojaner im Kampf gegen MetastasenKurt de Swaaf, 23. April 2013, 17:22
Listerien gelten normalerweise als gefährliche Erreger - Die Bakterien können aber auch genutzt werden, um eine Art nukleare Sprengköpfe in Krebszellen einzuschleusen
So mancher nennt ihn den schleichenden Tod. Das pankreatische duktale Adenokarzinom, besser bekannt als Bauchspeicheldrüsenkrebs, ist eine besonders heimtückische Krankheit. Die Geschwüre bilden bereits Metastasen, bevor sie aufgrund spezifischer Symptome entdeckt werden können. Die Tochtertumoren setzen sich vor allem in der Leber fest. Sie widerstehen klassischen Strahlen- und Chemotherapien und wachsen aggressiv weiter. Nur vier Prozent der Patienten überlebt länger als vier Jahre.
-------------------------------------------------
[*/QUOTE*]
mehr:
http://derstandard.at/1363708962117/Radioaktive-Trojaner-im-Kampf-gegen-Metastasen[*QUOTE*]
-------------------------------------------------
Public release date: 22-Apr-2013
Contact: Deirdre Branley
sciencenews@einstein.yu.eduTel: 001-718-430-3101
Albert Einstein College of Medicine
Radioactive bacteria targets metastatic pancreatic cancer
Novel approach using Listeria bacteria shows promise against a deadly disease VIDEO: Claudia Gravekamp, Ph.D., discusses her research on a new therapy for pancreatic cancer that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them. Dr. Gravekamp is...
Click here for more information.
April 22, 2013 — (BRONX, NY) — Researchers at Albert Einstein College of Medicine of Yeshiva University have developed a therapy for pancreatic cancer that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them. The experimental treatment dramatically decreased the number of metastases (cancers that have spread to other parts of the body) in a mouse model of highly aggressive pancreatic cancer without harming healthy tissue. The study was published today in the online edition of the Proceedings of the National Academy of Sciences.
"We're encouraged that we've been able to achieve a 90 percent reduction in metastases in our first round of experiments," said co-senior author Claudia Gravekamp, Ph.D., associate professor of microbiology & immunology at Einstein who studies new approaches to treating metastatic cancer. "With further improvements, our approach has the potential to start a new era in the treatment of metastatic pancreatic cancer."
[...]
The paper is titled "A non-toxic radioactive Listeria at is a highly effective therapy against metastatic pancreatic cancer." The other authors are Wilber Quispe-Tintaya, Ph.D., Dinesh Chandra, Ph.D., Arthee Jahangir, Matthew Harris and Arturo Casadevall, M.D., Ph.D., all at Einstein.
-------------------------------------------------
[*/QUOTE*]
VIDEO:http://www.eurekalert.org/multimedia/pub/55370.php?from=237619mehr:
http://www.eurekalert.org/pub_releases/2013-04/aeco-rbt041713.php"Science" Magazine: "Radioactive Microbes Nuke Tumor Cells"
http://news.sciencemag.org/sciencenow/2013/04/radioactive-microbes-nuke-tumor-.html?ref=hpClaudia Gravekamp, Ph.D.,
associate professor of microbiology & immunology at Einsteinhttp://www.einstein.yu.edu/faculty/11288/claudia-gravekamp/[*QUOTE*]
-------------------------------------------------
Contact
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Forchheimer Building, Room 407
Bronx, NY 10461
Tel: 001-718.430.4048
claudia.gravekamp[ett]einstein.yu.edu
-------------------------------------------------
[*/QUOTE*]
Albert Einstein College of Medicine of Yeshiva University
http://www.einstein.yu.edu/http://www.pnas.org/content/early/2013/04/17/1211287110.abstract[*QUOTE*]
-------------------------------------------------
Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancerWilber Quispe-Tintayaa,1, Dinesh Chandraa,1, Arthee Jahangira, Matthew Harrisb, Arturo Casadevalla, Ekaterina Dadachovab,2, and Claudia Gravekampa,2
Author Affiliations
Edited by E. Peter Greenberg, University of Washington, Seattle, WA, and approved March 15, 2013 (received for review July 3, 2012)
AbstractNo significant improvement in therapy of pancreatic cancer has been reported over the last 25 y, underscoring the urgent need for new alternative therapies. Here, we coupled a radioisotope, 188Rhenium, to an attenuated (at) live Listeria monocytogenes (Listeriaat) using Listeria-binding antibodies, thus creating a unique radioactive Listeriaat (RL). We then demonstrated in a highly metastatic pancreatic mouse tumor model (Panc-02) that RL delivered radioactivity to the metastases and less abundantly to primary tumors in vivo, without harming normal cells. This result was possible because Listeriaat was efficiently cleared by the immune system in normal tissues but not in the heavily immune-suppressed microenvironment of metastases and primary tumor. Multiple treatments with low doses of the RL resulted in a dramatic decrease in the number of metastases (?90%) compared with control groups in the Panc-02 model. This is the first report of using live attenuated bacteria delivering a highly radioactive payload to the metastases, resulting in killing tumor cells in vivo without harming normal cells. The nontoxic RL treatment is attractive for clinical development as a therapy to prevent pancreatic cancer recurrence and metastases.
Footnotes
1W.Q.-T. and D.C. contributed equally to this work.
2To whom correspondence may be addressed. E-mail: claudia.gravekamp[ett]einstein.yu.edu or ekaterina.dadachova[ett]einstein.yu.edu.
Author contributions: W.Q.-T., D.C., E.D., and C.G. designed research; W.Q.-T., D.C., A.J., M.H., E.D., and C.G. performed research; A.C., E.D., and C.G. contributed new reagents/analytic tools; W.Q.-T., D.C., E.D., and C.G. analyzed data; and W.Q.-T., D.C., E.D., and C.G. wrote the paper.
Conflict of interest statement: A.C., E.D., and C.G. have jointly filed a patent application related to the work of this manuscript.
This article is a PNAS Direct Submission.
This article contains supporting information online at
http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1211287110/-/DCSupplemental-------------------------------------------------
[*/QUOTE*]
Autor
Thema: Modifizierte Lysterien als radioaktive Trojaner im Kampf gegen Metastasen (Gelesen 1630 mal)